{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,11]],"date-time":"2026-09-11T02:40:15Z","timestamp":1789094415079,"version":"build-2803163510"},"reference-count":40,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,2,16]],"date-time":"2026-02-16T00:00:00Z","timestamp":1771200000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,3,25]],"date-time":"2026-03-25T00:00:00Z","timestamp":1774396800000},"content-version":"vor","delay-in-days":37,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"crossref","award":["72174166"],"award-info":[{"award-number":["72174166"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Cancer"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>China\u2019s Expedited Approval (EA) pathways, launched in 2005, aim to accelerate patient access to novel cancer therapies. Yet the clinical value and regulatory efficiency of oncology drugs approved under EA have not been comprehensively evaluated in a Chinese context or compared against global benchmarks.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>We conducted a cross-sectional analysis of all malignant hematology and oncology drugs granted EA by China\u2019s National Medical Products Administration between 2005 and 2021. Publicly available CDE reports, clinical trial registries, and literature sources were used to extract indication characteristics, review durations, trial design features, and ESMO-MCBS scores. Descriptive statistics summarized drug and trial features. Kruskal-Wallis tests compared median review times across factors; multiregional trial design and clinical benefit associations were explored qualitatively.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Ninety-nine drugs were granted expedited approval for 144 indications, 68% were small-molecule agents and 32% biologics; 86% underwent Priority Review, 28% Special Approval, and 24% Conditional Approval. Median review duration declined from over 1 000 days (2014&amp;2016) to ~\u2009300 days post-2015. Imported drugs (median 289 days) were reviewed faster than domestic ones (401 days). Of 137 pivotal trials supporting new indications, 70% were randomized and 66% parallel-controlled; primary endpoints were ORR (43%) and PFS (37%). Among 86 solid-tumor trials with ESMO-MCBS data, 34% achieved scores indicating meaningful clinical benefit (grades 4\u20135 or A\u2013B).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>China\u2019s EA program has markedly accelerated oncology drug approval timelines to levels approaching the EMA, though still trailing the FDA. While most pivotal trials used surrogate endpoints, only one-third of solid-tumor indications demonstrated high clinical benefit per ESMO-MCBS. To balance expedited access with therapeutic value, future reforms should emphasize early benefit assessment, real-world outcomes, and alignment of surrogate endpoints with overall survival benefits.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1186\/s12885-026-15749-1","type":"journal-article","created":{"date-parts":[[2026,2,16]],"date-time":"2026-02-16T04:52:50Z","timestamp":1771217570000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Accelerating cancer therapy review: a cross-sectional analysis of expedited approval in China, 2005\u20132021"],"prefix":"10.1186","volume":"26","author":[{"given":"Yun","family":"Tian","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xingyu","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xingchen","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaoyong","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shuchen","family":"Hu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaodong","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Caijun","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yu","family":"Fang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,2,16]]},"reference":[{"issue":"3","key":"15749_CR1","doi-asserted-by":"publisher","first-page":"229","DOI":"10.3322\/caac.21834","volume":"74","author":"F Bray","year":"2024","unstructured":"Bray F, Laversanne M, Sung H, et al. Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2024;74(3):229\u201363. https:\/\/doi.org\/10.3322\/caac.21834.","journal-title":"CA Cancer J Clin"},{"issue":"1","key":"15749_CR2","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1016\/j.jncc.2024.01.006","volume":"4","author":"B Han","year":"2024","unstructured":"Han B, Zheng R, Zeng H, et al. Cancer incidence and mortality in China, 2022. J Natl Cancer Cent. 2024;4(1):47\u201353. https:\/\/doi.org\/10.1016\/j.jncc.2024.01.006.","journal-title":"J Natl Cancer Cent"},{"key":"15749_CR3","doi-asserted-by":"publisher","first-page":"e943","DOI":"10.1016\/S2468-2667(23)00211-6","volume":"8","author":"J Qi","year":"2023","unstructured":"Qi J, Li M, Wang L, et al. National and subnational trends in cancer burden in China, 2005-20: an analysis of National mortality surveillance data. Lancet Public Health. 2023;8:e943\u201355. https:\/\/doi.org\/10.1016\/S2468-2667(23)00211-6.","journal-title":"Lancet Public Health"},{"issue":"5","key":"15749_CR4","doi-asserted-by":"publisher","first-page":"76","DOI":"10.1007\/s12032-022-01677-0","volume":"39","author":"P Sharma","year":"2022","unstructured":"Sharma P, Jhawat V, Mathur P, et al. Innovation in cancer therapeutics and regulatory perspectives. Med Oncol. 2022;39(5):76. https:\/\/doi.org\/10.1007\/s12032-022-01677-0.","journal-title":"Med Oncol"},{"issue":"3","key":"15749_CR5","doi-asserted-by":"publisher","first-page":"1690","DOI":"10.1021\/acs.jmedchem.3c02165","volume":"67","author":"DG Brown","year":"2024","unstructured":"Brown DG. A drug discovery perspective on FDA expedited development and incentive programs. J Med Chem. 2024;67(3):1690\u2013700. https:\/\/doi.org\/10.1021\/acs.jmedchem.3c02165.","journal-title":"J Med Chem"},{"issue":"5","key":"15749_CR6","doi-asserted-by":"publisher","first-page":"698","DOI":"10.1007\/s43441-022-00430-z","volume":"56","author":"G Beakes-Read","year":"2022","unstructured":"Beakes-Read G, Neisser M, Frey P, et al. Analysis of fda\u2019s accelerated approval program performance December 1992-December 2021. Ther Innov Regul Sci. 2022;56(5):698\u2013703. https:\/\/doi.org\/10.1007\/s43441-022-00430-z.","journal-title":"Ther Innov Regul Sci"},{"issue":"12","key":"15749_CR7","doi-asserted-by":"publisher","first-page":"4365","DOI":"10.1016\/j.apsb.2022.08.004","volume":"12","author":"Y Liu","year":"2022","unstructured":"Liu Y, Zhang N, Xie C, et al. Evolution of drug regulations and regulatory innovation for anticancer drugs in China. Acta Pharm Sin B. 2022;12(12):4365\u201377. https:\/\/doi.org\/10.1016\/j.apsb.2022.08.004.","journal-title":"Acta Pharm Sin B"},{"issue":"5","key":"15749_CR8","doi-asserted-by":"publisher","first-page":"1236","DOI":"10.1016\/j.drudis.2021.12.021","volume":"27","author":"S Wang","year":"2022","unstructured":"Wang S, Yang Q, Deng L, et al. An overview of cancer drugs approved through expedited approval programs and orphan medicine designation globally between 2011 and 2020. Drug Discov Today. 2022;27(5):1236\u201350. https:\/\/doi.org\/10.1016\/j.drudis.2021.12.021.","journal-title":"Drug Discov Today"},{"key":"15749_CR9","unstructured":"Announcement on Policies Pertaining to the Review and Approval of Drug Registration. http:\/\/www.gov.vn\/xinwen\/2015-11\/12\/content_2964893.htm. Accessed 27 Jan 2025."},{"key":"15749_CR10","unstructured":"Technical guidelines for drug conditional approach(tentative). http:\/\/www.cde.org.cn\/news.do?method=viewInfoCommon&id\u2009=\u2009315048. https:\/\/www.cde.org.cn\/main\/news\/viewInfoCommon\/d1716db06f90c3adf134de337373b22c. Accessed Jan 6, 2025."},{"key":"15749_CR11","doi-asserted-by":"publisher","first-page":"m3434","DOI":"10.1136\/bmj.m3434","volume":"371","author":"TJ Hwang","year":"2020","unstructured":"Hwang TJ, Ross JS, Vokinger KN, et al. Association between FDA and EMA expedited approval programs and therapeutic value of new medicines: retrospective cohort study. BMJ. 2020;371:m3434. https:\/\/doi.org\/10.1136\/bmj.m3434.","journal-title":"BMJ"},{"key":"15749_CR12","unstructured":"The Provisions for Drug Registration. National medical products administration. http:\/\/www.nmpa.gov.cn\/WS04\/CL2077\/376150.html. Accessed 27 Jan 2025."},{"issue":"18","key":"15749_CR13","first-page":"5","volume":"29","author":"XX Ren","year":"2018","unstructured":"Ren XX, Chen J, Shi LW. Analysis and thinking of speeding up new drug review and approval in China. China Pharmac. 2018;29(18):5.","journal-title":"China Pharmac"},{"issue":"22","key":"15749_CR14","first-page":"1781","volume":"45","author":"XY Chen","year":"2010","unstructured":"Chen XY, Zhang N, Peng J, et al. A systematic review and analysis of the application and approval of anticancer drugs in China from 2005 to 2010. Chin Pharm J. 2010;45(22):1781\u201385.","journal-title":"Chin Pharm J"},{"issue":"17","key":"15749_CR15","first-page":"5","volume":"22","author":"XY Chen","year":"2013","unstructured":"Chen XY, Zhang H, Gao CY, et al. Application and approval status of anti-cancer drugs in China between January 2011 and July 2013. Chin J New Drug. 2013;22(17):5.","journal-title":"Chin J New Drug"},{"issue":"6","key":"15749_CR16","doi-asserted-by":"publisher","first-page":"849","DOI":"10.1001\/jamaoncol.2017.5618","volume":"4","author":"JA Beaver","year":"2018","unstructured":"Beaver JA, Howie LJ, Pelosof L, et al. A 25-Year experience of US food and drug administration accelerated approval of malignant hematology and oncology drugs and biologics: A review. JAMA Oncol. 2018;4(6):849\u201356. https:\/\/doi.org\/10.1001\/jamaoncol.2017.5618.","journal-title":"JAMA Oncol"},{"key":"15749_CR17","unstructured":"The Review and Approval Process for Urgent Clinical Needs for Foreign Drug. (NMPA [2018] No.79). National Medical Product Administration. https:\/\/www.nmpa.gov.cn\/xxgk\/ggtg\/qtggtg\/20181030171201646.html. Accessed 27 Jan 2025."},{"issue":"12","key":"15749_CR18","doi-asserted-by":"publisher","first-page":"4365","DOI":"10.1016\/j.apsb.2022.08.004","volume":"12","author":"Y Liu","year":"2022","unstructured":"Liu Y, Zhang N, Xie C, et al. Evolution of drug regulations and regulatory innovation for anticancer drugs in China. Acta Pharm Sin B. 2022;12(12):4365\u201377. https:\/\/doi.org\/10.1016\/j.apsb.2022.08.004.","journal-title":"Acta Pharm Sin B"},{"key":"15749_CR19","doi-asserted-by":"publisher","unstructured":"Lythgoe MP, Desai A, Gyawali B et al. Cancer therapy approval Timings, review Speed, and publication of pivotal registration trials in the US and Europe,2010\u20132019.JAMA Netw open. 2022;5(6):e2216183. https:\/\/doi.org\/10.1001\/jamanetworkopen.2022.16183.","DOI":"10.1001\/jamanetworkopen.2022.16183"},{"issue":"2","key":"15749_CR20","doi-asserted-by":"publisher","first-page":"137","DOI":"10.1056\/NEJMoa2304594","volume":"389","author":"M Tsuboi","year":"2023","unstructured":"Tsuboi M, Herbst RS, John T, et al. Overall survival with osimertinib in resected EGFR-Mutated NSCLC. N Engl J Med. 2023;389(2):137\u201347.","journal-title":"N Engl J Med"},{"issue":"2","key":"15749_CR21","doi-asserted-by":"publisher","first-page":"218","DOI":"10.1016\/j.annonc.2020.10.600","volume":"32","author":"B Xu","year":"2021","unstructured":"Xu B, Sun T, Zhang Q, et al. Efficacy of Utidelone plus capecitabine versus capecitabine for heavily pretreated, anthracycline- and taxane-refractory metastatic breast cancer: final analysis of overall survival in a phase III randomised controlled trial. Ann Oncol. 2021;32(2):218\u201328. https:\/\/doi.org\/10.1016\/j.annonc.2020.10.600.","journal-title":"Ann Oncol"},{"issue":"1","key":"15749_CR22","doi-asserted-by":"publisher","first-page":"170","DOI":"10.1002\/cpt.2755","volume":"113","author":"X Luo","year":"2023","unstructured":"Luo X, Du X, Li Z, et al. Assessment of the delay in novel anticancer drugs between China and the united states: A comparative study of drugs approved between 2010 and 2021. Clin Pharmacol Ther. 2023;113(1):170\u201381. https:\/\/doi.org\/10.1002\/cpt.2755.","journal-title":"Clin Pharmacol Ther"},{"issue":"2","key":"15749_CR23","doi-asserted-by":"publisher","first-page":"211","DOI":"10.1038\/s43018-023-00696-8","volume":"5","author":"GS Mellgard","year":"2024","unstructured":"Mellgard GS, Fojo T, Bates SE. Lessons from withdrawn accelerated approvals in oncology. Nat Cancer. 2024;5(2):211\u201315. https:\/\/doi.org\/10.1038\/s43018-023-00696-8.","journal-title":"Nat Cancer"},{"key":"15749_CR24","unstructured":"Guidelines for clinical value-oriented research and development of oncology Therapeutics. https:\/\/www.cde.org.cn\/main\/news\/viewInfoCommon\/ef7bfde96c769308ad080bb7ab2f538e .Accessed 15 Nov 2022."},{"issue":"6","key":"15749_CR25","first-page":"521","volume":"33","author":"S Zhang","year":"2024","unstructured":"Zhang S, Yang L. Analysis of the effect of the accelerated approval process for antitumor drugs in the united States and its implications for China. Chin J New Drugs. 2024;33(6):521\u201330.","journal-title":"Chin J New Drugs"},{"issue":"12","key":"15749_CR26","doi-asserted-by":"publisher","first-page":"885","DOI":"10.1038\/s41571-023-00823-5","volume":"20","author":"A Walia","year":"2023","unstructured":"Walia A, Tuia J, Prasad V. Progression-free survival, disease-free survival and other composite end points in oncology: improved reporting is needed. Nat Rev Clin Oncol. 2023;20(12):885\u201395. https:\/\/doi.org\/10.1038\/s41571-023-00823-5.","journal-title":"Nat Rev Clin Oncol"},{"issue":"5","key":"15749_CR27","doi-asserted-by":"publisher","first-page":"728","DOI":"10.1001\/jamaoncol.2021.0379","volume":"7","author":"JC Del Paggio","year":"2021","unstructured":"Del Paggio JC, Berry JS, Hopman WM, et al. Evolution of the randomized clinical trial in the era of precision oncology. JAMA Oncol. 2021;7(5):728\u201334. https:\/\/doi.org\/10.1001\/jamaoncol.2021.0379.","journal-title":"JAMA Oncol"},{"key":"15749_CR28","doi-asserted-by":"publisher","first-page":"2474","DOI":"10.1002\/ijc.34473","volume":"152","author":"V Gloy","year":"2023","unstructured":"Gloy V, Schmitt AM, D\u00fcblin P, et al. The evidence base of US food and drug administration approvals of novel cancer therapies from 2000 to 2020. Int J Cancer. 2023;152:2474\u201384. https:\/\/doi.org\/10.1002\/ijc.34473.","journal-title":"Int J Cancer"},{"issue":"1","key":"15749_CR29","doi-asserted-by":"publisher","first-page":"69","DOI":"10.1186\/s13045-017-0439-6","volume":"10","author":"YK Shi","year":"2017","unstructured":"Shi YK, Jia B, Xu W, et al. Chidamide in relapsed or refractory peripheral T cell lymphoma:a multicenter real-world study in China. J Hematol Oncol. 2017;10(1):69. https:\/\/doi.org\/10.1186\/s13045-017-0439-6.","journal-title":"J Hematol Oncol"},{"key":"15749_CR30","unstructured":"Clinical trail consideration to support accelerated approval of oncology therapeutics. http:\/\/www.FDA.gov\/regulatory-information\/search-FDA-guidance-documents\/clinical-trial-considerations-support-accelerated-approval-oncology-therapeutics. Accessed 28 Jan 2025."},{"issue":"1","key":"15749_CR31","doi-asserted-by":"publisher","first-page":"151","DOI":"10.1177\/0962280217717761","volume":"28","author":"A Oulhaj","year":"2019","unstructured":"Oulhaj A, El Ghouch A, Holman RR. Testing for qualitative heterogeneity: an application to composite endpoints in survival analysis. Stat Methods Med Res. 2019;28(1):151\u201369. https:\/\/doi.org\/10.1177\/0962280217717761.","journal-title":"Stat Methods Med Res"},{"key":"15749_CR32","unstructured":"Clinical Trial Endpoints for the Approval of Advanced Non-small cell Lung Cancer. https:\/\/www.cde.org.cn\/zdyz\/domesticinfopage?zdyzIdCODE=c696c202109132c21a5a89ad49410e96. Accessed 30 Nov 2024."},{"key":"15749_CR33","unstructured":"Clinical Trial Endpoints for the Approval of Hepatocellular Carcinoma. https:\/\/www.cde.org.cn\/zdyz\/domesticinfopage?zdyzIdCODE=3a10a78525b1d41607873eaf0fec791f. Accessed 30 Nov 2024."},{"key":"15749_CR34","unstructured":"Clinical Trial Endpoints for the Approval of Prostate Cancer. https:\/\/www.cde.org.cn\/zdyz\/domesticinfopage?zdyzIdCODE=565ad185a04af6eb723122c1d42e4dcd. Accessed 14 Mar 2025."},{"issue":"12","key":"15749_CR35","doi-asserted-by":"publisher","first-page":"885","DOI":"10.1038\/s41571-023-00823-5","volume":"20","author":"A Walia","year":"2023","unstructured":"Walia A, Tuia J, Prasad V. Progression-free survival, disease-free survival and other composite end points in oncology: improved reporting is needed. Nat Rev Clin Oncol. 2023;20(12):885\u201395. https:\/\/doi.org\/10.1038\/s41571-023-00823-5.","journal-title":"Nat Rev Clin Oncol"},{"key":"15749_CR36","unstructured":"Guiding Principles for the Application of Patient-Reported Endpoints in Clinical Research and Development of Drugs. https:\/\/www.cde.org.cn\/main\/news\/viewInfoCommon\/c2f79c22e8678241b030c71523eb300c. Accessed 27 Dec 2024."},{"issue":"8","key":"15749_CR37","doi-asserted-by":"publisher","first-page":"e2225973","DOI":"10.1001\/jamanetworkopen.2022.25973","volume":"5","author":"Y Zhang","year":"2022","unstructured":"Zhang Y, Naci H, Wagner AK, et al. Overall survival benefits of cancer drugs approved in China from 2005 to 2020. JAMA Netw Open. 2022;5(8):e2225973. https:\/\/doi.org\/10.1001\/jamanetworkopen.2022.25973.","journal-title":"JAMA Netw Open"},{"issue":"8","key":"15749_CR38","doi-asserted-by":"publisher","first-page":"e222685","DOI":"10.1001\/jamahealthforum.2022.2685","volume":"3","author":"KN Vokinger","year":"2022","unstructured":"Vokinger KN, Kesselheim AS, Glaus CEG, et al. Therapeutic value of drugs granted accelerated approval or conditional marketing authorization in the US and Europe from 2007 to 2021. JAMA Health Forum. 2022;3(8):e222685. https:\/\/doi.org\/10.1001\/jamahealthforum.2022.2685.","journal-title":"JAMA Health Forum"},{"issue":"3","key":"15749_CR39","doi-asserted-by":"publisher","first-page":"e252026","DOI":"10.1001\/jamanetworkopen.2025.2026","volume":"8","author":"A Tibau","year":"2025","unstructured":"Tibau A, Hwang TJ, Romano A, et al. Factors in time to full approval or withdrawal for anticancer medicines granted accelerated approval by the FDA. JAMA Netw Open. 2025;8(3):e252026. https:\/\/doi.org\/10.1001\/jamanetworkopen.2025.2026.","journal-title":"JAMA Netw Open"},{"issue":"5","key":"15749_CR40","doi-asserted-by":"publisher","first-page":"1111","DOI":"10.1093\/annonc\/mdx053","volume":"28","author":"A Vivot","year":"2017","unstructured":"Vivot A, Jacot J, Zeitoun JD, et al. Clinical benefit, price and approval characteristics of FDA-approved new drugs for treating advanced solid cancer, 2000\u20132015. Ann Oncol. 2017;28(5):1111\u20131. https:\/\/doi.org\/10.1093\/annonc\/mdx053.","journal-title":"Ann Oncol"}],"container-title":["BMC Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12885-026-15749-1","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12885-026-15749-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12885-026-15749-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,16]],"date-time":"2026-06-16T18:17:56Z","timestamp":1781633876000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1186\/s12885-026-15749-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,2,16]]},"references-count":40,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["15749"],"URL":"https:\/\/doi.org\/10.1186\/s12885-026-15749-1","relation":{},"ISSN":["1471-2407"],"issn-type":[{"value":"1471-2407","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,2,16]]},"assertion":[{"value":"25 June 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"12 February 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 February 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This study was based exclusively on publicly available data from regulatory documents and clinical trial registries and did not involve human participants, human biological materials, or identifiable personal data. Therefore, in accordance with local regulations and the Declaration of Helsinki, ethical approval from an institutional review board or ethics committee was not required.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"390"}}